Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas

23 Jul 2024

Abstract excerpt

ABSTRACT: T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on the advances in chimeric antigen receptor-modified T cells and bispecific antibodies, first providing an overview of each product type, followed by exploring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39042891
DOI: 10.1182/bloodadvances.2021004535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasPMID 39042891Read ↗

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in CanadaSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Next-Generation Chimeric Antigen Receptor T-cellsSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancySemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Four challenges to CAR T cells breaking the glass ceilingSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategiesSemantic proximity Read ↗

T Cell Activation Machinery: Form and Function in Natural and Engineered Immune ReceptorsSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.